Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China

Andrologia

Volumn 43, Issue 3, 2011, Pages 208-212

  He, L ^a   Wen, J ^a   Jiang, X ^a   Chen, H ^a   Tang, Y ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Erectile dysfunction; Pharmacologic treatment of erectile dysfunction; Prostaglandin E1

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CHINA; CORPUS CAVERNOSUM; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; ECCHYMOSIS; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INJECTION PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYOFIBROSIS; PATIENT SATISFACTION; PRIAPISM; SEXUAL FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; ALPROSTADIL; ERECTILE DYSFUNCTION; HUMANS; IMPOTENCE, VASCULOGENIC; INJECTIONS; MALE; MIDDLE AGED; PENILE ERECTION; PENIS; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 79955805625     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2010.01091.x     Document Type: Article

References (20)

1. Chen J, Godschalk M, Katz PG, Mulligan T (1995) The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction. J Urol 153:80-81.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54-61.
3. Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G, Kalinderis A (1998) Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol 159:1921-1926.
4. Hauck EW, Altinkilic BM, Schroeder-Printzen I, Rudnick J, Weidner W (1999) Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5years. Andrologia 31(Suppl 1):99-103.
5. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460-463.
6. Kattan S (1995) Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. Urology 45:1032-1036.
7. Kim ED, McVary KT (1995) Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 153:1828-1830.
8. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C (2009) PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 15:3464-3475.
9. Lee LM, Stevenson RW, Szasz G (1989) Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 141:549-550.
10. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, Resnick MI (1989) Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141:54-57.
11. Linsenmeyer TA (2009) Treatment of erectile dysfunction following spinal cord injury. Curr Urol Rep 10:478-484.
12. Lue TF (2000) Erectile dysfunction. N Engl J Med 342:1802-1813.
13. Masson P, Lambert SM, Brown M, Shabsigh R (2005) PDE-5 inhibitors: current status and future trends. Urol Clin North Am 32:511-525.
14. McMahon CN, Smith CJ, Shabsigh R (2006) Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 332:589-592.
15. Montorsi F, Salonia A, Deho F, Cestari A, Guazzoni G, Rigatti P, Stief C (2003) Pharmacological management of erectile dysfunction. BJU Int 91:446-454.
16. Perimenis P, Konstantinopoulos A, Perimeni PP, Gyftopoulos K, Kartsanis G, Liatsikos E, Athanasopoulos A (2006) Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 8:219-224.
17. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319-326.
18. Shah PJ, Dinsmore W, Oakes RA, Hackett G (2007) Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 23:2577-2583.
19. Virag R (1999) Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 54:1073-1077.
20. Waldhauser M, Schramek P (1988) Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 140:525-527.